1910 Genetics is integrating AI, computation and biological automation to accelerate drug discovery. The current pharmaceutical R&D model is unsustainable, taking 12 to 15 years to bring new drugs to market, costing billions of dollars and having a success rate lower than 10%. 1910 Genetics is using their proprietary machine learning platforms to circumvent these problems by shortening the timeline and reducing operational costs of drug development. Their platforms, ELVIS and ROSALYND, are being employed for novel hit discovery, hit-to-lead and lead optimization for both small molecule and protein therapeutics. 1910 Genetics’ pipeline is disease agnostic, advancing drug discovery for all major diseases.

1910 Genetics is integrating AI, computation and biological automation to accelerate drug discovery. The current pharmaceutical R&amp;D model is unsustainable, taking 12 to 15 years to bring new drugs to market, costing billions of dollars and having a success rate lower than 10%. 1910 Genetics is using their proprietary machine learning platforms to circumvent these problems by shortening the timeline and reducing operational costs of drug development. Their platforms, ELVIS and ROSALYND, are being employed for novel hit discovery, hit-to-lead and lead optimization for both small molecule and protein therapeutics. 1910 Genetics’ pipeline is disease agnostic, advancing drug discovery for all major diseases.

1910 Genetics

20n Bio is using computational biology to design novel molecules such as protein therapeutics. At the core of 20n Bio’s philosophy is their open source platform for synthetic biology. Synthetic biology involves using the blueprint of DNA to make molecules biologically and more sustainably. 20n has used their approach to invent organisms that make acetaminophen/paracetamol (APAP) by fermenting sugar. 20n achieved this by engineering an E.coli and a yeast with a gene from a mushroom and over-expression of two native genes. The entire supply of APAP can be generated from petroleum. By using deep learning and biochemistry, 20n offers their Bioreachable Service platform to help teams identify new molecules, or discover more efficient ways to reach a product.

20n Bio is using computational biology to design novel molecules such as protein therapeutics. At the core of 20n Bio’s philosophy is their open source platform for synthetic biology. Synthetic biology involves using the blueprint of DNA to make molecules biologically and more sustainably. 20n has used their approach to invent organisms that make acetaminophen/paracetamol (APAP) by fermenting sugar. 20n achieved this by engineering an E.coli and a yeast with a gene from a mushroom and over-expression of two native genes. The entire supply of APAP can be generated from petroleum. By using deep learning and biochemistry, 20n offers their Bioreachable Service platform to help teams identify new molecules, or discover more efficient ways to reach a product.

20n Bio

3DBio Therapeutics is implanting 3D-bioprinted living tissues in patients. Living tissue implants are regenerative medicines that can be built from a patient’s own healthy tissue. 3DBio is generating personalized tissue implants using their four-part technology platform including their proprietary 3D-bioprinter (GMPrint), bio-ink (ColVivo), specialized cell culture and implantable protective shells. These implants are patient-matched and patient-derived, and 3DBio’s first product, AuriNovo, is being tested in clinical trials in adults and children. AuriNovi is created from a small biopsy on the patient’s ear remnant which is then used by 3DBio to print new, normally-shaped ears. The newly created ear is implanted into the patient clinically.

3DBio Therapeutics is implanting 3D-bioprinted living tissues in patients. Living tissue implants are regenerative medicines that can be built from a patient’s own healthy tissue. 3DBio is generating personalized tissue implants using their four-part technology platform including their proprietary 3D-bioprinter (GMPrint), bio-ink (ColVivo), specialized cell culture and implantable protective shells. These implants are patient-matched and patient-derived, and 3DBio’s first product, AuriNovo, is being tested in clinical trials in adults and children. AuriNovi is created from a small biopsy on the patient’s ear remnant which is then used by 3DBio to print new, normally-shaped ears. The newly created ear is implanted into the patient clinically.

3DBio Therapeutics

3T Biosciences is identifying novel targets for the treatment of solid tumors and other immune-mediated diseases. Current treatment options for solid tumors often have limited or negligible efficacy.  3T is understanding how the immune system recognises, targets and destroys cancer cells to develop novel immunotherapies. To develop immunotherapies, 3T is using their proprietary, novel technology called 3T-TRACE (T cell receptor antigen and cross-reactivity engine) to identify novel targets and therapeutically active T cell receptors (TCRs) and TCR mimetics (TCRm). 3T-TRACE employs machine learning and high-diversity target libraries to create highly specific, safe and more effective cancer treatments. 

3T Biosciences is identifying novel targets for the treatment of solid tumors and other immune-mediated diseases. Current treatment options for solid tumors often have limited or negligible efficacy. 3T is understanding how the immune system recognises, targets and destroys cancer cells to develop novel immunotherapies. To develop immunotherapies, 3T is using their proprietary, novel technology called 3T-TRACE (T cell receptor antigen and cross-reactivity engine) to identify novel targets and therapeutically active T cell receptors (TCRs) and TCR mimetics (TCRm). 3T-TRACE employs machine learning and high-diversity target libraries to create highly specific, safe and more effective cancer treatments.

3T Biosciences

4D Molecular Therapeutics is designing and developing transformative gene therapies for unmet medical conditions. Adeno-associated viruses (AAVs) have great potential for targeted delivery and efficient transduction of gene therapies. 4D is using their Therapeutic Vector Evolution platform to discover custom and proprietary AAVs for specific tissues and diseases to build a diverse vector library. Selected vectors are chosen and tested in non-human primates based on their Target Vector Profile for a disease. Subsequent testing is performed in human cell and organotypic tissue assays. 4D is developing a diverse pipeline of product candidates for cardiology, pulmonology and ophthalmology with products in early clinical trials.

4D Molecular Therapeutics is designing and developing transformative gene therapies for unmet medical conditions. Adeno-associated viruses (AAVs) have great potential for targeted delivery and efficient transduction of gene therapies. 4D is using their Therapeutic Vector Evolution platform to discover custom and proprietary AAVs for specific tissues and diseases to build a diverse vector library. Selected vectors are chosen and tested in non-human primates based on their Target Vector Profile for a disease. Subsequent testing is performed in human cell and organotypic tissue assays. 4D is developing a diverse pipeline of product candidates for cardiology, pulmonology and ophthalmology with products in early clinical trials.

4D Molecular Therapeutics

64x Bio is discovering new mammalian cell lines to transform cell and gene therapy manufacturing. To develop and manufacture cell therapies, cell lines that are easy to manipulate, engineer and grow are required. 64x Bio is using their VectorSelect platform to generate highly optimized cell lines that meet the requirements for production of cell therapies. In particular, 64x Bio is enhancing the efficiency of cell lines to manufacture viral vectors that improve manufacturing capacity and reduce overall cost. This involves high-throughput genome engineering, screening technologies and 64x Bio’s proprietary genetic barcoding method that connects information of viral vector productivity back to the parent cell which produced it.

64x Bio is discovering new mammalian cell lines to transform cell and gene therapy manufacturing. To develop and manufacture cell therapies, cell lines that are easy to manipulate, engineer and grow are required. 64x Bio is using their VectorSelect platform to generate highly optimized cell lines that meet the requirements for production of cell therapies. In particular, 64x Bio is enhancing the efficiency of cell lines to manufacture viral vectors that improve manufacturing capacity and reduce overall cost. This involves high-throughput genome engineering, screening technologies and 64x Bio’s proprietary genetic barcoding method that connects information of viral vector productivity back to the parent cell which produced it.

64x Bio

8Biomed is developing oxygen-based therapies to save and sustain lives. Oxygen is essential to all tissues and organs to survive. Within the body, oxygen is most efficiently transported by hemoglobin in the blood. However, oxygen can come under short supply during first responses to traumatic blood loss, organ transplants and conditions such as anemia and ischemia. 8Biomed has created a product intended to supply oxygen similarly to how blood supplies it. 8Biomed’s product works at the molecular scale and is derived from bovine blood through a process that yields highly-purified hemoglobin. The highly scalable purification of hemoglobin is then incorporated into 8Biomed’s product and can then be used with any blood type. Currently the product is awaiting completion and FDA-approval. 

8Biomed is developing oxygen-based therapies to save and sustain lives. Oxygen is essential to all tissues and organs to survive. Within the body, oxygen is most efficiently transported by hemoglobin in the blood. However, oxygen can come under short supply during first responses to traumatic blood loss, organ transplants and conditions such as anemia and ischemia. 8Biomed has created a product intended to supply oxygen similarly to how blood supplies it. 8Biomed’s product works at the molecular scale and is derived from bovine blood through a process that yields highly-purified hemoglobin. The highly scalable purification of hemoglobin is then incorporated into 8Biomed’s product and can then be used with any blood type. Currently the product is awaiting completion and FDA-approval.

8Biomed

A-Alpha Bio is accelerating drug discovery by providing cell-based tools of protein interactions. Protein interactions govern all cellular processes and are therefore linked with disease.  However, while predictive tools are now available for an individual protein structure, understanding protein interactions requires time-consuming experimentation. A-Alpha is circumventing this by generating high-quality protein-protein interaction data by measuring millions of protein-protein interactions at a time using AlphaSeq. AlphaSeq combines yeast two-hybrid technology with DNA barcodes to read out high-affinity interactions. This approach can be used to discover effective antibodies and degradable neo-substrates, engineer protein interfaces, and fuel predictive machine learning models. 

A-Alpha Bio is accelerating drug discovery by providing cell-based tools of protein interactions. Protein interactions govern all cellular processes and are therefore linked with disease. However, while predictive tools are now available for an individual protein structure, understanding protein interactions requires time-consuming experimentation. A-Alpha is circumventing this by generating high-quality protein-protein interaction data by measuring millions of protein-protein interactions at a time using AlphaSeq. AlphaSeq combines yeast two-hybrid technology with DNA barcodes to read out high-affinity interactions. This approach can be used to discover effective antibodies and degradable neo-substrates, engineer protein interfaces, and fuel predictive machine learning models.

A-Alpha Bio

A2 Biotherapeutics is designing novel cell therapies to treat serious illnesses. Therapeutics to treat cancers depend on methods to distinguish tumors from normal cells. A2 Bio is using their proprietary Tmod platform to innovate new treatments for solid tumors involving the immune system. The platform integrates multiple signals, overcoming conventional single-target therapies, and exploits tumor-specific vulnerabilities. The Tmod platform is robustly different from other cell therapy systems due to its tumor precision and efficacy by incorporating two receptors, an activator and a blocker, to modulate the immune system. As their platform is modular, A2 Bio is building a broad pipeline of both autologous and allogeneic cell therapies for many unexploited tumor targets. 

A2 Biotherapeutics is designing novel cell therapies to treat serious illnesses. Therapeutics to treat cancers depend on methods to distinguish tumors from normal cells. A2 Bio is using their proprietary Tmod platform to innovate new treatments for solid tumors involving the immune system. The platform integrates multiple signals, overcoming conventional single-target therapies, and exploits tumor-specific vulnerabilities. The Tmod platform is robustly different from other cell therapy systems due to its tumor precision and efficacy by incorporating two receptors, an activator and a blocker, to modulate the immune system. As their platform is modular, A2 Bio is building a broad pipeline of both autologous and allogeneic cell therapies for many unexploited tumor targets.

A2 Biotherapeutics

AavantiBio is using gene transfer and gene editing to develop new therapies to treat genetic diseases. Precision genetic medicine technologies have the potential to treat or cure many serious genetic diseases with significant unmet need. Beginning with Friedreich’s ataxia, AavantiBio is building a platform combining their technology with chemistry and manufacturing to create many therapeutic modalities. Critical to AavantiBio’s approach is transient immunomodulation, to prevent immune responses to adeno-associated viruses that deliver the genetic payload. AavantiBio is using comprehensive preclinical and clinical data to support their immunomodulation method. Currently, AavantiBio’s pipeline is in preclinical stages with promising efficacy and safety in mice, rats and non-human primates.

AavantiBio is using gene transfer and gene editing to develop new therapies to treat genetic diseases. Precision genetic medicine technologies have the potential to treat or cure many serious genetic diseases with significant unmet need. Beginning with Friedreich’s ataxia, AavantiBio is building a platform combining their technology with chemistry and manufacturing to create many therapeutic modalities. Critical to AavantiBio’s approach is transient immunomodulation, to prevent immune responses to adeno-associated viruses that deliver the genetic payload. AavantiBio is using comprehensive preclinical and clinical data to support their immunomodulation method. Currently, AavantiBio’s pipeline is in preclinical stages with promising efficacy and safety in mice, rats and non-human primates.

AavantiBio

AB Studio is enhancing the potential and scalability of antibody-based therapeutics. There are many different types of antibodies that vary by target antigen, size and functionality. AB Studio is developing complex antibodies with enhanced efficacy, safety, and manufacturability features that have potential applications for treatment of cancer and infectious diseases. AB Studio depends upon computer-aided antibody design (CAAD) for therapeutic antibody discovery, lead selection, engineering, humanization and optimization. Antibodies made by AB Studio have been used in a variety of cases from developing tri-specific antibodies for COVID-19 to the creation of novel “imbalanced” bi-specific antibodies. 

AB Studio is enhancing the potential and scalability of antibody-based therapeutics. There are many different types of antibodies that vary by target antigen, size and functionality. AB Studio is developing complex antibodies with enhanced efficacy, safety, and manufacturability features that have potential applications for treatment of cancer and infectious diseases. AB Studio depends upon computer-aided antibody design (CAAD) for therapeutic antibody discovery, lead selection, engineering, humanization and optimization. Antibodies made by AB Studio have been used in a variety of cases from developing tri-specific antibodies for COVID-19 to the creation of novel “imbalanced” bi-specific antibodies.

AB Studio

Abalone Bio is developing antibody drugs that target receptors on the surface of cells to treat diseases. G-protein coupled receptors (GPCRs) are important for cellular health and frequently get disrupted in disease, yet many remain undruggable by small molecules. Antibodies are also limited to only blocking, not activating, GPCRs. Abalone is changing this by finding both activating or inhibiting bioactive antibodies that target GPCRs. To discover these antibodies, Abalone is combining engineered living cells with data-driven computation, which is compatible with different types of antibodies. Abalone’s first therapeutic focus is immune system regulators that cause inflammatory diseases and cancer.

Abalone Bio is developing antibody drugs that target receptors on the surface of cells to treat diseases. G-protein coupled receptors (GPCRs) are important for cellular health and frequently get disrupted in disease, yet many remain undruggable by small molecules. Antibodies are also limited to only blocking, not activating, GPCRs. Abalone is changing this by finding both activating or inhibiting bioactive antibodies that target GPCRs. To discover these antibodies, Abalone is combining engineered living cells with data-driven computation, which is compatible with different types of antibodies. Abalone’s first therapeutic focus is immune system regulators that cause inflammatory diseases and cancer.

Abalone Bio

Abata Therapeutics is understanding the biology of T cells to create therapies for autoimmune diseases. Regulatory T cells (Tregs) are a critical component of the immune system that act to suppress the immune response preventing autoimmunity. Abata is using this knowledge to engineer Tregs as targeted therapies that stop immune-mediated destruction of normal cells and restore homeostasis. Treg engineering involves expression of a T cell receptor that recognizes a tissue-restricted antigen, to selectively target the therapy to the site of disease for a robust response. In addition, engineered Tregs are optimized for durability allowing the effects of a single dose to last years. Abata has initial programs for multiple sclerosis and Type 1 diabetes.

Abata Therapeutics is understanding the biology of T cells to create therapies for autoimmune diseases. Regulatory T cells (Tregs) are a critical component of the immune system that act to suppress the immune response preventing autoimmunity. Abata is using this knowledge to engineer Tregs as targeted therapies that stop immune-mediated destruction of normal cells and restore homeostasis. Treg engineering involves expression of a T cell receptor that recognizes a tissue-restricted antigen, to selectively target the therapy to the site of disease for a robust response. In addition, engineered Tregs are optimized for durability allowing the effects of a single dose to last years. Abata has initial programs for multiple sclerosis and Type 1 diabetes.

Abata Therapeutics

Abeona Therapeutics is developing cell and gene therapies for patients with serious diseases. Delivery of gene therapies to the desired tissue without causing an immune response is important for their success. Abeona is using their next-generation adeno-associated viruses (AAVs) to selectively deliver genetic payloads to the central nervous system, lungs, eyes, muscle, liver and other tissues. Abeona’s AAVs are non-replicating and have shown potential to evade immune responses generated by exposure to naturally-occuring AAV vectors. Abeona is applying their AAV technology for several diseases with therapies already in clinical trials. This includes EB-101, in Phase III trials for patients with Epidermolysis Bullosa and other undisclosed targets in preclinical phases.

Abeona Therapeutics is developing cell and gene therapies for patients with serious diseases. Delivery of gene therapies to the desired tissue without causing an immune response is important for their success. Abeona is using their next-generation adeno-associated viruses (AAVs) to selectively deliver genetic payloads to the central nervous system, lungs, eyes, muscle, liver and other tissues. Abeona’s AAVs are non-replicating and have shown potential to evade immune responses generated by exposure to naturally-occuring AAV vectors. Abeona is applying their AAV technology for several diseases with therapies already in clinical trials. This includes EB-101, in Phase III trials for patients with Epidermolysis Bullosa and other undisclosed targets in preclinical phases.

Abeona Therapeutics

Abintus Bio is reprogramming cells in vivo to pioneer off-the-shelf medicines. In vivo medicines involve approaches to treat disease by targeting cells within the body instead of first removing them. Abintus is using their Modular Viral Platform (MVP) to discover mechanisms to reprogram any cell type in the body to target a range of diseases. This involves identifying biologics to achieve reprogramming and methods to attain tissue specificity. Currently, Abintus has developed in vivo CAR-X products that can be used to reprogram both innate and adaptive immune effector cells to trigger a robust immune response against hematologic and solid tumors. 

Abintus Bio is reprogramming cells in vivo to pioneer off-the-shelf medicines. In vivo medicines involve approaches to treat disease by targeting cells within the body instead of first removing them. Abintus is using their Modular Viral Platform (MVP) to discover mechanisms to reprogram any cell type in the body to target a range of diseases. This involves identifying biologics to achieve reprogramming and methods to attain tissue specificity. Currently, Abintus has developed in vivo CAR-X products that can be used to reprogram both innate and adaptive immune effector cells to trigger a robust immune response against hematologic and solid tumors.

Abintus Bio

Abiosciences is using single-cell technology to understand the molecular basis of human diseases. Discovery of new drug targets and therapies can be fueled by building by the pioneering technology that enables information of gene expression and protein abundance of a diseased single cell. By combining their single cell techniques and metadata analysis platform, Abiosciences is developing proprietary drug targets that can be licensed, accelerating the drug discovery process and lowering overall costs. Abiosciences either invites interested partners to license therapeutics leads or co-develops them. In addition, Abiosciences offers bioinformatics services to aid other researchers process the large amount of data received through single-cell omics.

Abiosciences is using single-cell technology to understand the molecular basis of human diseases. Discovery of new drug targets and therapies can be fueled by building by the pioneering technology that enables information of gene expression and protein abundance of a diseased single cell. By combining their single cell techniques and metadata analysis platform, Abiosciences is developing proprietary drug targets that can be licensed, accelerating the drug discovery process and lowering overall costs. Abiosciences either invites interested partners to license therapeutics leads or co-develops them. In addition, Abiosciences offers bioinformatics services to aid other researchers process the large amount of data received through single-cell omics.

Abiosciences

Absci

Accelevir Diagnostics is developing methods to detect rare analytes in infectious diseases. To reduce the spread of infectious diseases, assays are required that enable quick and accurate diagnostics. Combining expertise in virology, immunology and assay commercialization, Accelevir is creating scalable assays that can identify difficult to detect pathogens. The technology employed includes droplet-digital PCR, qPCR and sequencing that offer high sensitivity. Accelevir is initially focusing on advancing new assays for persistent HIV-1, the virus that causes AIDS, and other clinically important viral infections. These assays can be used to support basic science research and to evaluate clinical trials. 

Accelevir Diagnostics is developing methods to detect rare analytes in infectious diseases. To reduce the spread of infectious diseases, assays are required that enable quick and accurate diagnostics. Combining expertise in virology, immunology and assay commercialization, Accelevir is creating scalable assays that can identify difficult to detect pathogens. The technology employed includes droplet-digital PCR, qPCR and sequencing that offer high sensitivity. Accelevir is initially focusing on advancing new assays for persistent HIV-1, the virus that causes AIDS, and other clinically important viral infections. These assays can be used to support basic science research and to evaluate clinical trials.

Accelevir Diagnostics

Accent Therapeutics is pioneering the field of epitranscriptomics to develop precision cancer therapies. Epitranscriptomics refers to a collection of RNA-modifying proteins (RMPs) that control many aspects of RNA biology and are critical drivers of specific cancers. Accent is using this insight to target RMPs with potent drug molecules to create precision cancer medicines. To date, few inhibitors of RMPs have been reported. Accent is using cutting-edge approaches with a robust chemical biology platform to identify and prioritize the most critical RMP targets and small molecules with favorable pharmacological properties, oral bioavailability and efficacy. Accent’s multi-parametric approach to lead optimization will position them to create clinic-ready molecules.

Accent Therapeutics is pioneering the field of epitranscriptomics to develop precision cancer therapies. Epitranscriptomics refers to a collection of RNA-modifying proteins (RMPs) that control many aspects of RNA biology and are critical drivers of specific cancers. Accent is using this insight to target RMPs with potent drug molecules to create precision cancer medicines. To date, few inhibitors of RMPs have been reported. Accent is using cutting-edge approaches with a robust chemical biology platform to identify and prioritize the most critical RMP targets and small molecules with favorable pharmacological properties, oral bioavailability and efficacy. Accent’s multi-parametric approach to lead optimization will position them to create clinic-ready molecules.

Accent Therapeutics

ACELYRIN is investing in, developing and commercializing life-changing drug therapies. ACELYRIN’s approach is to identify and develop therapeutics through efficient and ongoing collaborations with academia, big-pharma and early-stage start-ups to get the right expertise throughout the entire process. ACELYRIN’s lead candidate is izokibep, a monoclonal antibody mimetic to inhibit  interleukin-17A (IL-17A) with high potency and tissue penetrance. Currently, ACELYRIN is actively investigating the potential of izokibep in diseases with perturbed IL-17A signaling. This includes Phase 2/3 trials for inflammatory diseases of the eye (Uveitis) and skin (Psoriatic Arthritis). 

ACELYRIN is investing in, developing and commercializing life-changing drug therapies. ACELYRIN’s approach is to identify and develop therapeutics through efficient and ongoing collaborations with academia, big-pharma and early-stage start-ups to get the right expertise throughout the entire process. ACELYRIN’s lead candidate is izokibep, a monoclonal antibody mimetic to inhibit interleukin-17A (IL-17A) with high potency and tissue penetrance. Currently, ACELYRIN is actively investigating the potential of izokibep in diseases with perturbed IL-17A signaling. This includes Phase 2/3 trials for inflammatory diseases of the eye (Uveitis) and skin (Psoriatic Arthritis).

ACELYRIN

Acepodia is building a pipeline of cell therapies for various cancers. Given the recent advances in cell therapy and cutting edge technologies, Acepodia is developing the most potent immune cell lines possible to engage cancer cells. This involves using Acepodia’s proprietary platform technologies to equip the immune cells with optimal tumor targeting mechanisms such as their Antibody-Cell Conjugation (ACC) technology. ACC uses live-cell compatible chemistry to link any tumor-targeting antibody to the surface of human cells, enabling Acepodia to create a powerful, off-the-shelf cancer cell therapy to fight both solid tumors and hematological malignancies. Acepodia is using their discoveries to build a diverse pipeline, with their lead cell therapy in Phase 1 clinical trials.

Acepodia is building a pipeline of cell therapies for various cancers. Given the recent advances in cell therapy and cutting edge technologies, Acepodia is developing the most potent immune cell lines possible to engage cancer cells. This involves using Acepodia’s proprietary platform technologies to equip the immune cells with optimal tumor targeting mechanisms such as their Antibody-Cell Conjugation (ACC) technology. ACC uses live-cell compatible chemistry to link any tumor-targeting antibody to the surface of human cells, enabling Acepodia to create a powerful, off-the-shelf cancer cell therapy to fight both solid tumors and hematological malignancies. Acepodia is using their discoveries to build a diverse pipeline, with their lead cell therapy in Phase 1 clinical trials.

Acepodia

Achieve Life Sciences is developing and commercializing smoking cessation aids. More than 87% of lung cancer deaths, 61% of pulmonary deaths and 32% of coronary heart disease deaths are attributable to smoking and exposure to secondhand smoke. Even e-cigarettes are harmful due to chemical exposure that causes lung injury. Achieve is dedicated to addressing this global smoking health and nicotine addiction epidemic through the commercialization of their product cytisinicline. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic receptors in the brain to reduce withdrawal symptoms. A Phase 3 clinical trial using cytisinicline is now in progress for smoking cessation. 

Achieve Life Sciences is developing and commercializing smoking cessation aids. More than 87% of lung cancer deaths, 61% of pulmonary deaths and 32% of coronary heart disease deaths are attributable to smoking and exposure to secondhand smoke. Even e-cigarettes are harmful due to chemical exposure that causes lung injury. Achieve is dedicated to addressing this global smoking health and nicotine addiction epidemic through the commercialization of their product cytisinicline. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic receptors in the brain to reduce withdrawal symptoms. A Phase 3 clinical trial using cytisinicline is now in progress for smoking cessation.

Achieve Life Sciences

Acrivon Therapeutics is using a proteomics-based approach to develop precision oncology therapeutics. While the underlying basis of cancer is genomic alterations, it is the dysregulated proteome that drives the disease. Proteomic biomarkers therefore offer a more accurate matching of patients with drugs than genomic biomarkers. Acrivon is using their proprietary Predictive Precision Proteomics platform to develop patient selection tumor biopsy tests, called OncoSignature® tests, to identify which patients will benefit from a specific drug, matching drug mechanisms to the biologic drivers of cancer. Acrivon’s clinical pipeline is currently focused on advanced assets targeting the DNA damage response where traditional patient selection is challenging, with Phase 2 trials initiated.

Acrivon Therapeutics is using a proteomics-based approach to develop precision oncology therapeutics. While the underlying basis of cancer is genomic alterations, it is the dysregulated proteome that drives the disease. Proteomic biomarkers therefore offer a more accurate matching of patients with drugs than genomic biomarkers. Acrivon is using their proprietary Predictive Precision Proteomics platform to develop patient selection tumor biopsy tests, called OncoSignature® tests, to identify which patients will benefit from a specific drug, matching drug mechanisms to the biologic drivers of cancer. Acrivon’s clinical pipeline is currently focused on advanced assets targeting the DNA damage response where traditional patient selection is challenging, with Phase 2 trials initiated.

Acrivon Therapeutics

Acutis Diagnostics is using their expertise in infectious diseases to innovate diagnostic technologies and procedures. Reliable testing for infectious diseases, substance use, medication monitoring and oncology necessitates minimal errors. Acutis is striving for no errors by advancing medical testing with industry-leading turnaround time using their disease product line, Acutis RevealTM. For example, Acutis used their technology to detect COVID-19 including the emerging global variants that shows >99% sensitivity and 100% specificity within their test environment. However, Acutis delivers more than just test results, but also offers insights, support and access to their staff so that patients can understand their data.

Acutis Diagnostics is using their expertise in infectious diseases to innovate diagnostic technologies and procedures. Reliable testing for infectious diseases, substance use, medication monitoring and oncology necessitates minimal errors. Acutis is striving for no errors by advancing medical testing with industry-leading turnaround time using their disease product line, Acutis RevealTM. For example, Acutis used their technology to detect COVID-19 including the emerging global variants that shows &gt;99% sensitivity and 100% specificity within their test environment. However, Acutis delivers more than just test results, but also offers insights, support and access to their staff so that patients can understand their data.

Acutis Diagnostics

Adagio Therapeutics

Adaptive Phage Therapeutics (APT) is advancing therapies that treat multidrug resistant infections. Antimicrobial resistance (AMR) due to bacterial evolution limits the effectiveness and useful lifespan of many therapeutic antibiotics continuing to create a world-wide crisis. APT is addressing this problem by targeting the emergence of future antibiotic-resistant bacteria with bacteriophages (“phages”) that are the most prolific killers of bacteria. Phages are specific to bacteria and overcome challenges caused by antibiotics such as evolvability to new resistant strains, safety to human cells and the range of bacteria affected - typically a single phage targets a single bacterial strain. APT is growing a PhageBankTM to find phages that target resistant bacterial pathogens. 

Adaptive Phage Therapeutics (APT) is advancing therapies that treat multidrug resistant infections. Antimicrobial resistance (AMR) due to bacterial evolution limits the effectiveness and useful lifespan of many therapeutic antibiotics continuing to create a world-wide crisis. APT is addressing this problem by targeting the emergence of future antibiotic-resistant bacteria with bacteriophages (“phages”) that are the most prolific killers of bacteria. Phages are specific to bacteria and overcome challenges caused by antibiotics such as evolvability to new resistant strains, safety to human cells and the range of bacteria affected - typically a single phage targets a single bacterial strain. APT is growing a PhageBankTM to find phages that target resistant bacterial pathogens.

Adaptive Phage Therapeutics

Adcentrx Therapeutics is using protein conjugate technology to create therapies for cancer and other diseases. Antibody-drug conjugates (ADCs) are a therapeutic approach that deliver toxic payloads into a diseased cell. However, ADCs come with limitations such as fast clearance leading to lower efficacy and premature release of payloads causing off-target toxicity. Adcentrx is using their “Toolbox” to pioneer stable conjugation chemistry they refer to as the i-ConjugationTM technology. Using this technology, Adcentrx is improving payload delivery to the target, allowing higher dosing and better tumor penetration. In addition, Adecntrx is optimizing the targeting moiety, linker and payload to reduce manufacturing complexity and to tackle heterogeneous tumors. 

Adcentrx Therapeutics is using protein conjugate technology to create therapies for cancer and other diseases. Antibody-drug conjugates (ADCs) are a therapeutic approach that deliver toxic payloads into a diseased cell. However, ADCs come with limitations such as fast clearance leading to lower efficacy and premature release of payloads causing off-target toxicity. Adcentrx is using their “Toolbox” to pioneer stable conjugation chemistry they refer to as the i-ConjugationTM technology. Using this technology, Adcentrx is improving payload delivery to the target, allowing higher dosing and better tumor penetration. In addition, Adecntrx is optimizing the targeting moiety, linker and payload to reduce manufacturing complexity and to tackle heterogeneous tumors.

Adcentrx Therapeutics

Adicet Bio is developing T cell therapies to treat cancer. Gamma delta T cells recognise and eliminate diseased or cancerous cells making them well suited as cancer therapies. Moreover, these cells function in a MHC-independent manner which means they can be used in non-host settings without causing graft vs. host disease reducing risk. However, gamma delta T cells comprise a small fraction of blood cells. To overcome this, Adicet is creating universal off-the-shelf genetically modified gamma delta T cells that selectively target tumors. Adicent has shown that these cells show anti-tumor activity in vitro and in vivo mouse models and are now entering clinical trials while building their broad cancer pipeline.

Adicet Bio is developing T cell therapies to treat cancer. Gamma delta T cells recognise and eliminate diseased or cancerous cells making them well suited as cancer therapies. Moreover, these cells function in a MHC-independent manner which means they can be used in non-host settings without causing graft vs. host disease reducing risk. However, gamma delta T cells comprise a small fraction of blood cells. To overcome this, Adicet is creating universal off-the-shelf genetically modified gamma delta T cells that selectively target tumors. Adicent has shown that these cells show anti-tumor activity in vitro and in vivo mouse models and are now entering clinical trials while building their broad cancer pipeline.

Adicet Bio

Aditum Bio is a new model of biotech venture capital that is focused on acquiring and translating scientific discoveries into innovative therapies. The three words that best describe Aditum’s approach are agile, inventive and responsive. Their approach brings together unmatched scientific and domain expertise with agile operational capabilities. Aditum’s approach revolves around identifying and selecting innovative drug candidates with unrecognized potential. By specializing in the translational phase of drug discovery, Aditum hopes they can develop best-in-class therapies for a broad range of diseases, reach more patients and create faster returns for their investors.

Aditum Bio is a new model of biotech venture capital that is focused on acquiring and translating scientific discoveries into innovative therapies. The three words that best describe Aditum’s approach are agile, inventive and responsive. Their approach brings together unmatched scientific and domain expertise with agile operational capabilities. Aditum’s approach revolves around identifying and selecting innovative drug candidates with unrecognized potential. By specializing in the translational phase of drug discovery, Aditum hopes they can develop best-in-class therapies for a broad range of diseases, reach more patients and create faster returns for their investors.

Aditum Bio

adMare BioInnovations

Admera Health is designing advanced molecular diagnostics and pharmacogenomics (PGx) solutions to facilitate personalized medicine and non-invasive cancer testing. PGx involves understanding the relationship between a person's genetic makeup and their response to different drugs to develop effective and safe medications tailored to the individual. Admera has built their flagship product, PGxOne Plus, that incorporates next-generation gene sequencing design applications and expert data curation to offer a comprehensive test built to enable smarter and safer medication management. Admera’s portfolio of genetic tests also include OncoGxOne for solid tumor profiling and CardioGxOne for cardiovascular disease conditions.

Admera Health is designing advanced molecular diagnostics and pharmacogenomics (PGx) solutions to facilitate personalized medicine and non-invasive cancer testing. PGx involves understanding the relationship between a person&#39;s genetic makeup and their response to different drugs to develop effective and safe medications tailored to the individual. Admera has built their flagship product, PGxOne Plus, that incorporates next-generation gene sequencing design applications and expert data curation to offer a comprehensive test built to enable smarter and safer medication management. Admera’s portfolio of genetic tests also include OncoGxOne for solid tumor profiling and CardioGxOne for cardiovascular disease conditions.

Admera Health

Adverum Biotechnologies is creating one-time gene therapies for patients with ocular and rare diseases. These gene therapies provide durable expression of therapeutic proteins that are lacking in diseased patients. To identify effective vectors to deliver the gene therapies, Adverum is using multi-step directed evolution that screens millions of different Adeno-associated viruses’ (AAVs) capsid genes for novel properties such as cell type specificity. Following novel vector discovery, selected optimized AAVs can be produced using Adverum’s highly scalable manufacturing process. Adverum is advancing a pipeline of gene therapies for ocular diseases such as ADVM-022 for age-related macular degeneration which has entered clinical trials.

Adverum Biotechnologies is creating one-time gene therapies for patients with ocular and rare diseases. These gene therapies provide durable expression of therapeutic proteins that are lacking in diseased patients. To identify effective vectors to deliver the gene therapies, Adverum is using multi-step directed evolution that screens millions of different Adeno-associated viruses’ (AAVs) capsid genes for novel properties such as cell type specificity. Following novel vector discovery, selected optimized AAVs can be produced using Adverum’s highly scalable manufacturing process. Adverum is advancing a pipeline of gene therapies for ocular diseases such as ADVM-022 for age-related macular degeneration which has entered clinical trials.

Adverum Biotechnologies

adyn is applying precision medicine to personalized birth control methods. Birth control methods are important for the health of females, yet many methods, such as the pill, cause side effects for many individuals. As birth control is used as a medicine for many conditions from Premenstrual Syndrome to Polycystic Ovary Syndrome, side effects should not be present. By understanding an individual's unique preferences and biology, adyn has built The Birth Control Test that can determine the most effective birth control method without side effects. The test calculates whether an individual's genetic background and hormone levels puts them at risk for certain side effects. Following the test, adyn puts customer’s in touch with a competent medical provider to review the data and offer advice.

adyn is applying precision medicine to personalized birth control methods. Birth control methods are important for the health of females, yet many methods, such as the pill, cause side effects for many individuals. As birth control is used as a medicine for many conditions from Premenstrual Syndrome to Polycystic Ovary Syndrome, side effects should not be present. By understanding an individual&#39;s unique preferences and biology, adyn has built The Birth Control Test that can determine the most effective birth control method without side effects. The test calculates whether an individual&#39;s genetic background and hormone levels puts them at risk for certain side effects. Following the test, adyn puts customer’s in touch with a competent medical provider to review the data and offer advice.

adyn

Aeglea BioTherapeutics is using human enzyme therapeutics to treat patients with rare metabolic diseases. Metabolism describes the network of life sustaining chemical reactions needed for health. Rare metabolic diseases typically result from a missing or defective enzyme which is needed to convert chemicals and therefore causes aberrant activity within a cell. Aeglea is using protein engineering to create enzyme-based therapeutics that are engineered to target the primary driver of metabolic diseases. Enzyme engineering involves either developing enzymes that possess advanced properties of existing enzymes or generating enzymes with novel activity. Aeglea is initially focusing on three diseases with ineffective treatment options: Homocystinuria, Arginase 1 Deficiency and Cystinuria.

Aeglea BioTherapeutics is using human enzyme therapeutics to treat patients with rare metabolic diseases. Metabolism describes the network of life sustaining chemical reactions needed for health. Rare metabolic diseases typically result from a missing or defective enzyme which is needed to convert chemicals and therefore causes aberrant activity within a cell. Aeglea is using protein engineering to create enzyme-based therapeutics that are engineered to target the primary driver of metabolic diseases. Enzyme engineering involves either developing enzymes that possess advanced properties of existing enzymes or generating enzymes with novel activity. Aeglea is initially focusing on three diseases with ineffective treatment options: Homocystinuria, Arginase 1 Deficiency and Cystinuria.

Aeglea BioTherapeutics

Aether Bio is repurposing biologics to create new compounds. Enzymes are proteins that catalyze a variety of biochemical reactions, often at lower temperatures and higher yields than chemical production. Aether is using their platform to rapidly engineer enzymes to manufacture complex and novel products at reduced cost and time. The platform involves searching trillions of enzymes within the protein sequence space to find novel biocatalysts - by mapping the sequence space, Aether can make a searchable index. Aether’s proprietary hardware and automation enables experiments to be massively parallelized which allows Aether to build a large database for further exploration. Aether sees synthetic biology as the key approach to build the future, with automation and enzymes as the catalyst.

Aether Bio is repurposing biologics to create new compounds. Enzymes are proteins that catalyze a variety of biochemical reactions, often at lower temperatures and higher yields than chemical production. Aether is using their platform to rapidly engineer enzymes to manufacture complex and novel products at reduced cost and time. The platform involves searching trillions of enzymes within the protein sequence space to find novel biocatalysts - by mapping the sequence space, Aether can make a searchable index. Aether’s proprietary hardware and automation enables experiments to be massively parallelized which allows Aether to build a large database for further exploration. Aether sees synthetic biology as the key approach to build the future, with automation and enzymes as the catalyst.

Aether Bio

Affini-T Therapeutics is using the power of T cells to develop therapies for solid tumor cancers. T cells exhibit a cytotoxic response against tumor cells; however, T cells are repressed by the tumor cells in many cancers. Affini-T is using synthetic biology and gene editing to engineer TCR T cell therapies to target oncogenic driver mutations that cause tumors by increasing their activity. Both CD8+ and CD4+ are engineered by Affini-T to further enhance the cytotoxic response and sustained killing of tumor cells as well as to persist longer in the tumor microenvironment. With their discovery platform, Affini-T is building many oncogenic driver programs including KRAS G12V and mutant p53 that are in early development.

Affini-T Therapeutics is using the power of T cells to develop therapies for solid tumor cancers. T cells exhibit a cytotoxic response against tumor cells; however, T cells are repressed by the tumor cells in many cancers. Affini-T is using synthetic biology and gene editing to engineer TCR T cell therapies to target oncogenic driver mutations that cause tumors by increasing their activity. Both CD8+ and CD4+ are engineered by Affini-T to further enhance the cytotoxic response and sustained killing of tumor cells as well as to persist longer in the tumor microenvironment. With their discovery platform, Affini-T is building many oncogenic driver programs including KRAS G12V and mutant p53 that are in early development.

Affini-T Therapeutics

Affinia Therapeutics is enhancing gene therapies by expanding the potential of adeno-associated viruses (AAVs). AAVs are the vectors that target cells and deliver gene therapies. Affinia is using their Affinia Rationally-designed Therapies (ART) platform to improve the efficacy, safety, and manufacturability of AAVs for gene therapies. This involves re-engineering AAVs with improved tissue targeting, finding novel promoters to control gene expression levels, and new cell lines and transfection agents to enhance quality, yields, and scalability. Affinia’s current pipeline is focused on nervous system diseases, including cancers affecting the brain. These diseases are difficult to target due to the blood brain barrier, which Affinia hopes their approach will overcome.

Affinia Therapeutics is enhancing gene therapies by expanding the potential of adeno-associated viruses (AAVs). AAVs are the vectors that target cells and deliver gene therapies. Affinia is using their Affinia Rationally-designed Therapies (ART) platform to improve the efficacy, safety, and manufacturability of AAVs for gene therapies. This involves re-engineering AAVs with improved tissue targeting, finding novel promoters to control gene expression levels, and new cell lines and transfection agents to enhance quality, yields, and scalability. Affinia’s current pipeline is focused on nervous system diseases, including cancers affecting the brain. These diseases are difficult to target due to the blood brain barrier, which Affinia hopes their approach will overcome.

Affinia Therapeutics

Affinivax is developing a next-generation approach in vaccine technologies. The Centers for Disease Control and Prevention estimates that 4% of patients will contract a healthcare-associated infection each year due to antimicrobial resistance. Affinivax is addressing antimicrobial resistance with their patented technology platform called the Multiple Antigen Presentation System (MAPSTM) to develop several vaccines. The MAPSTM platform simplifies vaccine design and selects for key immunogenic epitopes to induce robust immune protection in a single vaccine.

The novel vaccines designed by Affinivax are to be tested against challenging infectious diseases. AFX3772, their lead vaccine candidate for Streptococcus pneumoniae, is expected to be tested in Phase 3 clinical trials this year.

Affinivax is developing a next-generation approach in vaccine technologies. The Centers for Disease Control and Prevention estimates that 4% of patients will contract a healthcare-associated infection each year due to antimicrobial resistance. Affinivax is addressing antimicrobial resistance with their patented technology platform called the Multiple Antigen Presentation System (MAPSTM) to develop several vaccines. The MAPSTM platform simplifies vaccine design and selects for key immunogenic epitopes to induce robust immune protection in a single vaccine.
The novel vaccines designed by Affinivax are to be tested against challenging infectious diseases. AFX3772, their lead vaccine candidate for Streptococcus pneumoniae, is expected to be tested in Phase 3 clinical trials this year.

Affinivax

AgBiome analyzes the microbiome of plants to create innovative products for agriculture. Securing the global food production process is fundamental to feeding the world responsibly. AgBiome is contributing by using their microbial discovery platform to develop innovative biological products that enhance global food production. The platform involves AgBiome’s microbial collection that comes from isolating microbes in environmental samples from across the globe and fully sequencing their genomes. From this, AgBiome is using their identification system, GENESISTM, to discover new insect control genes, find target candidates for pest control and ultimately build a large intellectual property portfolio that can be licensed. 

AgBiome analyzes the microbiome of plants to create innovative products for agriculture. Securing the global food production process is fundamental to feeding the world responsibly. AgBiome is contributing by using their microbial discovery platform to develop innovative biological products that enhance global food production. The platform involves AgBiome’s microbial collection that comes from isolating microbes in environmental samples from across the globe and fully sequencing their genomes. From this, AgBiome is using their identification system, GENESISTM, to discover new insect control genes, find target candidates for pest control and ultimately build a large intellectual property portfolio that can be licensed.

AgBiome

Agena Biosciences is advancing rapid and accurate genetic testing solutions including viral RNA detection of COVID-19. While sequencing-based technologies are commonly used in diagnostics, they are highly complex, expensive and have a long turnaround time. Agena has instead developed a suite of MassARRAY panels that enable accurate, high-throughput, and low cost detection of viruses such as SARS-CoV-2. Agena also provides Custom Assay services to design, develop and functionally verify assays for germline or somatic genotyping, translocations, copy number variants and methylation profiling. With these tools, Agena helps laboratories translate genomic discoveries into targeted, cost-effective testing.

Agena Biosciences is advancing rapid and accurate genetic testing solutions including viral RNA detection of COVID-19. While sequencing-based technologies are commonly used in diagnostics, they are highly complex, expensive and have a long turnaround time. Agena has instead developed a suite of MassARRAY panels that enable accurate, high-throughput, and low cost detection of viruses such as SARS-CoV-2. Agena also provides Custom Assay services to design, develop and functionally verify assays for germline or somatic genotyping, translocations, copy number variants and methylation profiling. With these tools, Agena helps laboratories translate genomic discoveries into targeted, cost-effective testing.

Agena Bioscience

Akero Therapeutics is developing treatments for patients with serious metabolic diseases. Many metabolic diseases, such as non-alcoholic steatohepatitis (NASH), are marked by high unmet medical need. NASH is caused by excess storage of fat in the liver which causes liver inflammation and scarring. Akero is using a licensed engineered protein called efruxifermin (EFX) and developing it to treat the metabolic dysfunction that occurs in NASH patients. EFX is a differentiated Fc-FGF21 fusion protein that mimics native FGF21 to alleviate cellular stress and regulate metabolism. Building on positive Phase 2a results, EFX is now being used in Phase 2b clinical trials in pre-cirrhotic patients.

Akero Therapeutics is developing treatments for patients with serious metabolic diseases. Many metabolic diseases, such as non-alcoholic steatohepatitis (NASH), are marked by high unmet medical need. NASH is caused by excess storage of fat in the liver which causes liver inflammation and scarring. Akero is using a licensed engineered protein called efruxifermin (EFX) and developing it to treat the metabolic dysfunction that occurs in NASH patients. EFX is a differentiated Fc-FGF21 fusion protein that mimics native FGF21 to alleviate cellular stress and regulate metabolism. Building on positive Phase 2a results, EFX is now being used in Phase 2b clinical trials in pre-cirrhotic patients.

Akero Therapeutics

Akouos is developing AAV-based gene therapies to treat hearing loss that results from mutations in genes for inner ear function. Akouos uses specialized vectors and surgical procedures to target the inner ear.

Akouos has exclusive rights to AAV vectors that were designed specifically for diseases of the inner ear, hearing, and balance. For example, the company uses a vector called Anc8OL65 that transduces sensory cells and cochlear cells with high efficiency. Akouos delivers their gene therapies via minimally invasive surgery along the sensory epithelium, where target cells of the inner ear are located. The therapies work by various mechanisms, including delivery of a healthy gene in loss-of-function mutations, delivery of RNAi, and delivery of a protein that alters a disease pathway.

Akouos is developing AAV-based gene therapies to treat hearing loss that results from mutations in genes for inner ear function. Akouos uses specialized vectors and surgical procedures to target the inner ear.
Akouos has exclusive rights to AAV vectors that were designed specifically for diseases of the inner ear, hearing, and balance. For example, the company uses a vector called Anc8OL65 that transduces sensory cells and cochlear cells with high efficiency. Akouos delivers their gene therapies via minimally invasive surgery along the sensory epithelium, where target cells of the inner ear are located. The therapies work by various mechanisms, including delivery of a healthy gene in loss-of-function mutations, delivery of RNAi, and delivery of a protein that alters a disease pathway.

Akouos

Alamar Biosciences is building a next-generation proteomic platform for plasma and liquid protein detection. Proteins present in blood samples have potential use as biomarkers for early detection and prevention of diseases, but many of these proteins are currently outside the detectable range due to their low abundance. Alamar is creating the most sensitive proteomic liquid biopsy platform that can profile thousands of proteins from microliters of blood. The fully automated platform achieves unparalleled sensitivity by using Alamar’s two breakthrough technologies: NULISA and Attobody. Together, Alamar’s platform can achieve single-digit attomolar detection, surpassing currently available technology and providing the potential to transform healthcare.

Alamar Biosciences is building a next-generation proteomic platform for plasma and liquid protein detection. Proteins present in blood samples have potential use as biomarkers for early detection and prevention of diseases, but many of these proteins are currently outside the detectable range due to their low abundance. Alamar is creating the most sensitive proteomic liquid biopsy platform that can profile thousands of proteins from microliters of blood. The fully automated platform achieves unparalleled sensitivity by using Alamar’s two breakthrough technologies: NULISA and Attobody. Together, Alamar’s platform can achieve single-digit attomolar detection, surpassing currently available technology and providing the potential to transform healthcare.

Alamar Biosciences

Alector is developing therapies for the treatment of neurodegenerative diseases. Despite the rise in the number of patients suffering with brain disorders there is still a lack of effective therapeutics. Immune cells in the brain are important for brain health. By combining antibody technology, human genetics and the latest insights in neuroscience, Alector is building a pipeline of therapeutics to harness the body’s own immune system to heal itself. This immuno-neurology strategy is analogous to current immuno-oncology approaches to activate and recruit the adaptive immune response. Through partnering with other companies such as GSK, Alector currently has many therapeutics in Phase 1-3 clinical trials for dementia and Alzheimer’s disease.

Alector is developing therapies for the treatment of neurodegenerative diseases. Despite the rise in the number of patients suffering with brain disorders there is still a lack of effective therapeutics. Immune cells in the brain are important for brain health. By combining antibody technology, human genetics and the latest insights in neuroscience, Alector is building a pipeline of therapeutics to harness the body’s own immune system to heal itself. This immuno-neurology strategy is analogous to current immuno-oncology approaches to activate and recruit the adaptive immune response. Through partnering with other companies such as GSK, Alector currently has many therapeutics in Phase 1-3 clinical trials for dementia and Alzheimer’s disease.

Alector

AlivaMab Discovery Services discovers and develops antibodies for research and therapeutics. Antibodies are used in a diverse range of applications, but take time to be manufactured with desired target antigen specificity. AlivaMab uses their transgenic animal, Ablexis’ AlivaMab® Mouse, that is optimized for the discovery of antibodies that can be moved seamlessly into development. The mouse is engineered such that antibodies possess naturally selected fully human variable domains breaking immune tolerance, while retaining strong, fast, high-affinity IgG responses. Multiple AlivaMab antibodies have entered clinical trials, both as standard antibodies and as advanced therapeutic modalities. AlivaMab also engineers antibodies against chimeric antigen receptors.

AlivaMab Discovery Services discovers and develops antibodies for research and therapeutics. Antibodies are used in a diverse range of applications, but take time to be manufactured with desired target antigen specificity. AlivaMab uses their transgenic animal, Ablexis’ AlivaMab® Mouse, that is optimized for the discovery of antibodies that can be moved seamlessly into development. The mouse is engineered such that antibodies possess naturally selected fully human variable domains breaking immune tolerance, while retaining strong, fast, high-affinity IgG responses. Multiple AlivaMab antibodies have entered clinical trials, both as standard antibodies and as advanced therapeutic modalities. AlivaMab also engineers antibodies against chimeric antigen receptors.

AlivaMab Discovery Services

Alkahest is developing treatments for neurodegenerative and age-related diseases. Many proteins that increase or decrease with age can be identified in the blood plasma. Alkahest is characterizing these proteins, known as chronokines, to create therapeutics to slow down or reverse age-related diseases. In particular, Alkahest is interested in chronokines involved in promoting restorative biological processes or pathological degenerative processes as therapeutic targets. Target identification follows the traditional pharmaceutical method, supplemented with Alkahest’s highly selected and refined plasma fractions. Using this approach, Alkahest has many product candidates in Phase 1 & 2 clinical trials.

Alkahest is developing treatments for neurodegenerative and age-related diseases. Many proteins that increase or decrease with age can be identified in the blood plasma. Alkahest is characterizing these proteins, known as chronokines, to create therapeutics to slow down or reverse age-related diseases. In particular, Alkahest is interested in chronokines involved in promoting restorative biological processes or pathological degenerative processes as therapeutic targets. Target identification follows the traditional pharmaceutical method, supplemented with Alkahest’s highly selected and refined plasma fractions. Using this approach, Alkahest has many product candidates in Phase 1 &amp; 2 clinical trials.

Alkahest

Alladapt Immunotherapeutics is identifying mechanisms to treat food allergies. Food allergy is a disease of the immune system that can be triggered by a range of common foods. For tens of millions of people, this immune response to certain foods is harmful, with potentially life-threatening consequences. As the underlying biology of food allergies grows, Alladapt is using these findings to develop a single therapeutic to support the management of a broad range of common food allergies. Alladapt’s lead drug candidate, ADP101, is being developed for the mitigation of food allergy provoked by either a single or multiple proteins from a wide range of foods. Alladapt hopes to formulate ADP101 as an oral prescription therapy that delivers highly consistent alleviation of allergies to patients.

Alladapt Immunotherapeutics is identifying mechanisms to treat food allergies. Food allergy is a disease of the immune system that can be triggered by a range of common foods. For tens of millions of people, this immune response to certain foods is harmful, with potentially life-threatening consequences. As the underlying biology of food allergies grows, Alladapt is using these findings to develop a single therapeutic to support the management of a broad range of common food allergies. Alladapt’s lead drug candidate, ADP101, is being developed for the mitigation of food allergy provoked by either a single or multiple proteins from a wide range of foods. Alladapt hopes to formulate ADP101 as an oral prescription therapy that delivers highly consistent alleviation of allergies to patients.

Alladapt Immunotherapeutics

Allakos is developing antibody-based therapeutics to treat allergic and inflammatory diseases. Eosinophils and mast cells, both types of immune cells, play a role in pathogenesis of many acute and chronic inflammatory diseases. Allakos is targeting receptors expressed on the surface of different immune cells with therapeutic antibodies. Allakos’ lead therapeutic target, AK002, binds a receptor on eosinophils to deplete them as they are elevated in patients with eosinophilic gastrointestinal diseases. The receptor is Siglec-8, which when activated by the antibody, induces apoptosis in eosinophils. Positive clinical activity of AK002 has already been seen and Allokos is continuing to test the drug in more eosinophil-driven diseases.

Allakos is developing antibody-based therapeutics to treat allergic and inflammatory diseases. Eosinophils and mast cells, both types of immune cells, play a role in pathogenesis of many acute and chronic inflammatory diseases. Allakos is targeting receptors expressed on the surface of different immune cells with therapeutic antibodies. Allakos’ lead therapeutic target, AK002, binds a receptor on eosinophils to deplete them as they are elevated in patients with eosinophilic gastrointestinal diseases. The receptor is Siglec-8, which when activated by the antibody, induces apoptosis in eosinophils. Positive clinical activity of AK002 has already been seen and Allokos is continuing to test the drug in more eosinophil-driven diseases.

Allakos

Allarta Life Science is advancing regenerative medicine approaches to create cell and stem cell therapies. Allarta’s proprietary platform is geared to create safe, durable and retrievable stem cell therapies. To achieve this, Allarta is focusing on three technologies: [1] Proprietary immune-privileged polymers, [2] next-generation microgels and [3] RT-Vaccine delivery. Technology improvement involves developing, synthesizing and characterizing novel polymers and materials that can enable cell encapsulation, facilitate cell attachment, assess immune protection or for cryoprotection. Allarta is initially developing their technology for diabetes and lysosomal storage disorders with the pipeline in preclinical studies.

Allarta Life Science is advancing regenerative medicine approaches to create cell and stem cell therapies. Allarta’s proprietary platform is geared to create safe, durable and retrievable stem cell therapies. To achieve this, Allarta is focusing on three technologies: [1] Proprietary immune-privileged polymers, [2] next-generation microgels and [3] RT-Vaccine delivery. Technology improvement involves developing, synthesizing and characterizing novel polymers and materials that can enable cell encapsulation, facilitate cell attachment, assess immune protection or for cryoprotection. Allarta is initially developing their technology for diabetes and lysosomal storage disorders with the pipeline in preclinical studies.

Allarta Life Science

Allay Therapeutics is pioneering products to help patients recover from post-surgical pain management. Current pain management products provide several days of pain relief, much shorter than the weeks or months of post-surgical recuperation that millions of patients cope with. To resolve this, Allay has developed the first technology designed to deliver weeks of localized pain management. Allay’s proprietary technology combines validated non-opioid analgesics and biopolymers to create candidates that deliver targeted pain relief. By tuning the drug-biopolymer architecture that alters the analgesic release profile, Allay can design their technology for a variety of potential applications. Allay’s lead candidate, ATX-101, is designed to support recuperation from total knee-replacement surgery.

Allay Therapeutics is pioneering products to help patients recover from post-surgical pain management. Current pain management products provide several days of pain relief, much shorter than the weeks or months of post-surgical recuperation that millions of patients cope with. To resolve this, Allay has developed the first technology designed to deliver weeks of localized pain management. Allay’s proprietary technology combines validated non-opioid analgesics and biopolymers to create candidates that deliver targeted pain relief. By tuning the drug-biopolymer architecture that alters the analgesic release profile, Allay can design their technology for a variety of potential applications. Allay’s lead candidate, ATX-101, is designed to support recuperation from total knee-replacement surgery.

Company, website	Founded	Location	Size	Funding
1. 1910 Genetics	2018	Boston, MA	1-50	10-50M
2. 20n Bio	2021	Philadelphia, PA	1-50	<10M
3. 3DBio Therapeutics	2014	Long Island City, NY	1-50	<10M
4. 3T Biosciences	2017	San Francisco, CA	1-50	10-100M
5. 4D Molecular Therapeutics	2013	Emeryville, CA	101-250	100-500M
6. 64x Bio	2018	San Francisco, CA	1-50	10-100M
7. 8Biomed	2018	Malvern, PA	1-50	not disclosed
8. A-Alpha Bio	2017	Seattle, WA	1-50	10-100M
9. A2 Biotherapeutics	2018	Agoura Hills, CA	51-100	100-500M
10. AavantiBio	2019	Cambridge, MA	1-50	100-500M
11. AB Studio	2017	Hayward, CA	1-50	not disclosed
12. Abalone Bio	2017	Emeryville, CA	1-50	<10M
13. Abata Therapeutics	2021	Cambridge, MA	1-50	50-100M
14. Abeona Therapeutics	2015	New York, NY	51-100	100-500M
15. Abintus Bio	2020	San Diego, CA	1-50	not disclosed
16. Abiosciences	2019	San Francisco, CA	1-50	not disclosed
17. Absci	2011	Vancouver, WA	101-250	100-500M
18. Accelevir Diagnostics	2015	Baltimore, MD	1-50	<10M
19. Accent Therapeutics	2017	Lexington, MA	1-50	100-500M
20. ACELYRIN	2020	Los Angeles, CA	1-50	100-500M
21. Acepodia	2016	Alameda, CA	1-50	100-500M
22. Achieve Life Sciences	2015	Seattle, WA	1-50	10-100M
23. Acrivon Therapeutics	2018	Cambridge, MA	1-50	100-500M
24. Acutis Diagnostics	2014	Hicksville, NY	101-250	no disclosed
25. Adagio Therapeutics	2020	Waltham, MA	51-100	100-500M
26. Adaptive Phage Therapeutics	2016	Gaithersburg, MD	1-50	50-100M
27. Adcentrx Therapeutics	2021	San Diego, CA	1-50	10-100M
28. Adicet Bio	2014	Menlo Park, CA	51-100	100-500M
29. Aditum Bio	2019	Oakland, CA	1-50	100-500M
30. adMare BioInnovations	2019	Vancouver, BC	101-250	10-100M
31. Admera Health	2014	South Plainfield, NJ	51-100	not disclosed
32. Adverum Biotechnologies	2012	Redwood City, CA	101-250	100-500M
33. adyn	2020	Seattle, WA	1-50	<10M
34. Aeglea BioTherapeutics	2013	Austin, TX	101-250	50-100M
35. Aether Bio	2017	Menlo Park, CA	1-50	not disclosed
36. Affini-T Therapeutics	2021	Watertown, MA	1-50	not disclosed
37. Affinia Therapeutics	2019	Waltham, MA	51-100	100-500M
38. Affinivax	2014	Cambridge, MA	101-250	100-500M
39. AgBiome	2012	Research Triangle Park, NC	101-250	100-500M
40. Agena Bioscience	2014	San Diego, CA	101-250	not disclosed
41. Akero Therapeutics	2017	San Francisco, CA	1-50	100-500M
42. Akouos	2016	Boston, MA	51-100	100-500M
43. Alamar Biosciences	2018	Fremont, CA	1-50	10-100M
44. Alector	2013	San Francisco, CA	101-250	100-500M
45. AlivaMab Discovery Services	2018	San Diego, CA	1-50	not disclosed
46. Alkahest	2014	San Carlos, CA	51-100	10-100M
47. Alladapt Immunotherapeutics	2018	Menlo Park, CA	1-50	10-100M
48. Allakos	2012	Redwood City, CA	101-250	100-500M
49. Allarta Life Science	2018	Hamilton, ON	1-50	<10M
50. Allay Therapeutics	2017	Menlo Park, CA	1-50	10-100M

Companies